Saab, Sammy <br/><br/>
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  Apr 2016 
 - 515-21 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1478-3231 
<br/><br/><label>Standard No.: </label>10.1111/liv.13033  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Anilides--economics<br/>Antiviral Agents--economics<br/>Carbamates--economics<br/>Cost-Benefit Analysis<br/>Cyclopropanes<br/>Drug Costs<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C--diagnosis<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Transplantation--adverse effects<br/>Macrocyclic Compounds--economics<br/>Male<br/>Markov Chains<br/>Middle Aged<br/>Models, Economic<br/>Phenotype<br/>Proline--analogs & derivatives<br/>Recurrence<br/>Ribavirin--economics<br/>Risk Factors<br/>Ritonavir--economics<br/>Sulfonamides--economics<br/>Time Factors<br/>Treatment Outcome<br/>United States<br/>Uracil--analogs & derivatives<br/>Valine<br/>Viral Load<br/>Virus Activation--drug effects